Volumen: 16 # Number : 1
Publication Date : Enero - Abril Year: 2012
Authors: Solessi M. Soledad, Ledesma L. Ignacio, Aliano Romina, Bezares R. Fernando
Abstract: Hairy cell leukemia is an indolent lymphoproliferative disease that is located within the group of mature B cell neoplasms (WHO classification of the year 2008)1. Today it has become a chronic disease with excellent prognosis due to the introduction of purine analogs, particularly pentostatin and cladribine, making possible to achieve complete remission rates around 90% with a median survival of approximately 16 years.3 Relapse rates range from 25-30% at 5 years follow-up and although several studies showed that schemes with rituximab at 375mg/m2 for 4 or 8 cycles are highly effective in eradicating MRD at the end of treatment, the impact on the prediction of relapse and disease-free survival is still controversial. The aim of this paper is to review the various therapeutic resources available, trying to figure out what is the best strategy in these patients both at diagnosis and at relapse, and correct timing for the start of treatment.
Key words: HCL, treatment, purine analogues
Pages : 33-41
|
